eFeedLink Mobile

 


June 26, 2020

 

Boehringer Ingelheim's Classical Swine Fever live vaccine gets approval

 

 

Boehringer Ingelheim announced that its China-developed Classical Swine Fever Vaccine, Live has recently obtained a "New Veterinary Drug Registration Certificate" from the Ministry of Agriculture and Rural Affairs of China.

 

C-strain, PK/WRL  Cell Line Origin or Ingelvac® CSF MLV (English trade name) is the first Classical Swine Fever live vaccine jointly developed by a multinational company and Chinese research institutes. It marks another milestone for Boehringer Ingelheim's "in China, for China", as the company is committed to providing innovative and high-quality swine vaccines for the Chinese swine industry, as well as holistic swine disease solutions to pig farms.

 

Classical Swine Fever (CSF) is a highly contagious and lethal infectious disease in pigs, caused by Classical Swine Fever Virus (CSFV). As the disease has caused huge economic losses to the pig farming industry, it is classified as Class A Animal Disease in China. Even though massive vaccination with CSF live vaccine in China now effectively controls the outbreak of CSF, endemic and sporadic spread still exists.

 

Most Classical Swine Fever live vaccines currently available on the market can only be stored at -15℃ for 18 months. Cold-chain transportation, storage and dilution all need a strict temperature control. The newly approved Ingelvac® CSF MLV uses state-of-the-art microcarrier-based suspension culture and freeze-drying technologies to ensure high-titer virus, stable vaccine production process, and controllable quality. It can be stored at 2-8℃ for 24 months. This high-quality product will provide China's pig farming industry with breakthrough immunisation programs and supporting disease solutions. It will contribute to the efforts and challenge of eradicating the Classical Swine Fever in China.

 

Ingelvac® CSF MLV will be produced by Boehringer Ingelheim's Taizhou plant, Jiangsu province, and it is expected to be commercialised in early 2021. It will become Boehringer Ingelheim's first swine vaccine product, developed, manufactured and distributed in China. The Taizhou plant already manufactures Ingelvac® PRRS MLV (live vaccine for porcine reproductive and respiratory syndrome).

 

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of EUR4 billion in 2019 and presence in more than 150 countries.

Share this article on FacebookShare this article on TwitterPrint this articleForward this article
ABOUT US
ENQUIRY
GENERAL
Copyright ©2020 eFeedLink. All rights reserved
Switch to Full Website